The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Pfizer faces challenges as share price shows mixed performance in 2025
Pfizer is navigating challenges, including a reinstated lawsuit affecting its diversity fellowship program, which has pressured its share price. As of January 9, 2025, shares closed at EUR 26.03, reflecting a slight decline, while UBS and JPMorgan maintain a "Neutral" rating with price targets of USD 29 and USD 30, respectively. Despite uncertainties, Pfizer reported strong fourth-quarter results, exceeding expectations with revenues of $17.76 billion, and is targeting sales of $61 to $64 billion for 2025.
cdc recommends lowering pneumococcal vaccine age boosting market potential
The CDC's advisory panel has recommended lowering the routine pneumococcal vaccination age from 65 to 50, potentially expanding the market for vaccines like Merck's Capvaxive and Pfizer's Prevnar. Analysts have adjusted sales forecasts, anticipating significant revenue growth for these vaccines, particularly for Merck in the near term, though competition from Vaxcyte's candidate may emerge by 2028.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.